Celldex Therapeutics, Inc. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Celldex Therapeutics, Inc. (CLDX) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$14.22 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2020-11-05
- Celldex Therapeutics, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-09-30 was -$14.22M.
- Celldex Therapeutics, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-06-30 was -$11.03M.
- Celldex Therapeutics, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2019-09-30 was -$11.41M.
- Celldex Therapeutics, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2019-06-30 was -$11.78M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month |
|---|---|---|---|
| 2020-09-30 | -$14.22M 10-Q · filed 2020-11-05 | -$25.25M derived: sum of 2 quarters · filed 2020-11-05 | -$37.88M 10-Q · filed 2020-11-05 |
| 2020-06-30 | -$11.03M 10-Q · filed 2020-08-06 | -$23.66M 10-Q · filed 2020-08-06 | |
| 2019-09-30 | -$11.41M 10-Q · filed 2020-11-05 | -$23.19M derived: sum of 2 quarters · filed 2020-11-05 | -$40.43M 10-Q · filed 2020-11-05 |
| 2019-06-30 | -$11.78M 10-Q · filed 2020-08-06 | -$29.02M 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |